Tag Archives: rituximab

Mella finds hypometabolic state in ME/CFS

Health rising blog post, by Cort Johnson, 15 October 2016: Another Hypometabolic Signature Found Fluge and Mella are best known for their Rituximab work, but just last week Mella reported that they’d found a hypometabolic state in ME/CFS as well. … Continue reading

Posted in News | Tagged , , , , , , , , , | Comments Off on Mella finds hypometabolic state in ME/CFS

New rituximab trial results from Norway

Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading

Posted in News | Tagged , , , , , | Comments Off on New rituximab trial results from Norway

Unexpected findings & promoting monocausal claims, a cautionary tale

Article abstract: Stories of serendipitous discoveries in medicine incorrectly imply that the path from an unexpected observation to major discovery is straightforward or guaranteed. In this paper, I examine a case from the field of research about chronic fatigue syndrome (CFS). In Norway, … Continue reading

Posted in News | Tagged , , , , | Comments Off on Unexpected findings & promoting monocausal claims, a cautionary tale

IIMEC 2016 conference report by Dr R Vallings

IIME 11 conference report by Dr Rosamund Vallings MB BS On 3rd June, 2016, I was privileged to attend the 11th Invest in ME – Research International conference in London – the theme being “A New Decade of Invest in ME … Continue reading

Posted in News | Tagged , , , , , , , , , , | Comments Off on IIMEC 2016 conference report by Dr R Vallings

People with ME/CFS have long been told it’s all in their head – these scientists disagree

The Canary blog, 8 June 2016, by Conrad Bower: CFS have long been told it’s all in their head – these scientists disagree A conference bringing together the brightest minds in Myalgic Encephalomyelitis a.k.a Chronic Fatigue Syndrome (ME/CFS) research, presented … Continue reading

Posted in News | Tagged , , , , , , | Comments Off on People with ME/CFS have long been told it’s all in their head – these scientists disagree

ME and rituximab in Notodden Norway

ME-foreldrene blog: Lecture by Hanne Thürmer, Notodden. RituxME and current development, 13 April 2016 Lecture by dr Hanne Thürmer, Notodden Hospital Original in Norwegian/Norsk original From a lecture given at the local department of the Norwegian ME-association in Notodden, avd … Continue reading

Posted in News | Tagged , , , | Comments Off on ME and rituximab in Notodden Norway

Video interview with parent Mary Dimmock about her son and rituximab

Episode 78 of Llewellyn King’s ME/CFS Alert videos interviews Mary Dimmock, whose son has ME and who is receiving RITUXAN (rituximab) treatment privately. (24 mins)    

Posted in News | Tagged , , , , , | Comments Off on Video interview with parent Mary Dimmock about her son and rituximab

CFS & Rituximab revisited

Science based medicine article: Chronic Fatigue Syndrome: Rituximab Revisited by Harriet Hall (the SkepDoc), January 19, 2016 Three years ago I wrote about an experimental treatment for chronic fatigue syndrome (CFS): rituximab (brand name Rituxan). I was concerned that doctors who … Continue reading

Posted in News | Tagged , , , , , , | 1 Comment

IiME rituximab research update

Invest in ME press release: Invest in ME (Research) has created a separate strand to our Biomedical Research Fund which will be explicitly used for this UK rituximab trial. A specific fund-raising thermometer was created just for this project – see  … Continue reading

Posted in News | Tagged , | Comments Off on IiME rituximab research update

B-cell function in patients with ME/CFS

Research summary: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a  heterogeneous condition of unknown etiology characterized by multiple symptoms including fatigue, post-exertional malaise and cognitive impairment, lasting for at least 6 months. Recently, two clinical trials of B-cell depletion therapy with rituximab (anti-CD20) reported convincing … Continue reading

Posted in News | Tagged , , | Comments Off on B-cell function in patients with ME/CFS